Iceni Pharmaceuticals ^Company

Bacteriophage based cancer therapies. Main focus: multiple myeloma. Iceni Pharmaceuticals develops cancer therapies, specialising in repurposing and reformulating existing drugs for new indications. Using this strategy, much of the cost and risk surrounding the drug development process can be reduced. Patients should benefit from more rapid availability of new treatments since they have already been through extensive clinical trials and their safety profiles are already well established. The benefit to investors and licensees is a de-risked development process, since manufacture (CMC), toxicity and regulatory affairs are already well-characterised.